ibrutinib,zanubrutinib
abbvie,beigene,janssen
['brukinsa', 'zanubrutinib', 'cll', ' ibru']
in r/r cll, #zanubrutinib offers 35% improved pfs over ibrutinib; edge greater for higher-risk patients #brukinsa #ash22 via 
Evidence-Based #Oncology. Bringing together perspectives of 20,000+ cancer care #providers, #payers, #policymakers, #patients, and researchers in #cancer care.